清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial

医学 临床终点 前列腺癌 土星 前列腺 肿瘤科 临床试验 转移 临床研究阶段 原发性肿瘤 内科学 癌症 天体物理学 行星 物理
作者
John Nikitas,Matthew B. Rettig,John Shen,Robert E. Reiter,Alan Lee,Michael L. Steinberg,Luca Valle,Ankush Sachdeva,Tahmineh Romero,Jérémie Calais,Johannes Czernin,Nicholas G. Nickols,Amar U. Kishan
出处
期刊:European Urology [Elsevier BV]
卷期号:85 (6): 517-520 被引量:8
标识
DOI:10.1016/j.eururo.2024.01.021
摘要

Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6 mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy. Patients received 6 mo of androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) and metastasis-directed SBRT. The primary endpoint was the percentage of patients with prostate-specific antigen (PSA) <0.05 ng/ml 6 mo after testosterone recovery (≥150 ng/dl), with the study powered to detect an improvement from 1% to 12%. We enrolled 28 men between March 2021 and June 2022. Median follow-up was 20 mo (interquartile range 16-22). Twenty-six patients (93%) completed SBRT with 6 mo of hormone therapy, of whom six discontinued at least one ARPI; two patients withdrew prematurely. At 6 mo after testosterone recovery, PSA was maintained at <0.05 ng/ml in 13/26 patients (50%, 95% confidence interval 32-67%). Rates of grade 2 and 3 AAT toxicity were 21% and 21%. The results confirm that addition of metastasis-directed SBRT to highly potent systemic therapy can maintain low PSA after testosterone recovery, although further studies are needed to clarify the optimal systemic therapy regimen. PATIENT SUMMARY: We tested a combination of intensified hormone therapy (called androgen annihilation therapy) and radiotherapy targeted at metastases in men with recurrence of metastatic prostate cancer. We found that half of patients were recurrence-free 6 months after their testosterone level recovered, and that less than a quarter of patients experienced a severe drug-related side effect. Overall, this appears to be an effective therapy with acceptable side effects. This trial is registered on ClinicalTrials.gov as NCT03902951.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
yzhilson完成签到 ,获得积分0
28秒前
可爱的函函应助葵小葵采纳,获得10
45秒前
共享精神应助容若采纳,获得10
1分钟前
tails完成签到,获得积分10
1分钟前
眼里的萧萧雨完成签到,获得积分20
1分钟前
深情安青应助科研通管家采纳,获得10
1分钟前
ding应助容若采纳,获得10
2分钟前
2分钟前
小宏发布了新的文献求助10
2分钟前
顾矜应助容若采纳,获得10
2分钟前
小宏完成签到,获得积分10
2分钟前
两个榴莲完成签到,获得积分0
4分钟前
Hello应助容若采纳,获得10
4分钟前
千里草完成签到,获得积分10
4分钟前
4分钟前
量子星尘发布了新的文献求助10
4分钟前
隐形曼青应助容若采纳,获得10
4分钟前
斯文败类应助研友_拓跋戾采纳,获得10
5分钟前
5分钟前
bsmark发布了新的文献求助10
5分钟前
5分钟前
爆米花应助bsmark采纳,获得10
6分钟前
不能吃太饱完成签到 ,获得积分10
6分钟前
桐桐应助容若采纳,获得10
7分钟前
激动的似狮完成签到,获得积分10
7分钟前
7分钟前
加贝完成签到 ,获得积分10
7分钟前
毛毛完成签到,获得积分10
7分钟前
灿烂而孤独的八戒完成签到 ,获得积分0
7分钟前
ph完成签到 ,获得积分10
8分钟前
隐形曼青应助容若采纳,获得10
8分钟前
8分钟前
bsmark发布了新的文献求助10
8分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分10
8分钟前
8分钟前
爆米花应助容若采纳,获得10
9分钟前
ximitona完成签到,获得积分10
9分钟前
ximitona发布了新的文献求助10
9分钟前
10分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
SOFT MATTER SERIES Volume 22 Soft Matter in Foods 1000
Zur lokalen Geoidbestimmung aus terrestrischen Messungen vertikaler Schweregradienten 1000
Rapid synthesis of subnanoscale high-entropy alloys with ultrahigh durability 666
Storie e culture della televisione 500
Selected research on camelid physiology and nutrition 500
《2023南京市住宿行业发展报告》 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4889508
求助须知:如何正确求助?哪些是违规求助? 4173518
关于积分的说明 12952156
捐赠科研通 3934961
什么是DOI,文献DOI怎么找? 2159148
邀请新用户注册赠送积分活动 1177466
关于科研通互助平台的介绍 1082396